Content about Bayer HealthCare

May 1, 2013
Bayer to acquire Conceptus for $1.1 billion

Bayer HealthCare will buy birth-control product maker Conceptus for $1.1 billion, the companies said.

LEVERKUSEN, Germany — Bayer HealthCare will buy birth-control product maker Conceptus for $1.1 billion, the companies said.

Bayer said its $31-per-share purchase of the Mountain View, Calif.-based company would allow it to expand its selection of contraception products. Conceptus makes Essure, a non-surgical permanent birth-control method, and Bayer said it would allow the company to offer a complete range of short-term, long-term and permanent contraceptive methods for women.

March 12, 2013
Former Bayer executive wins CHPA award

The former president of Bayer HealthCare's Worldwide Consumer Care Division has won a lifetime-achievement award from a trade group focused on the OTC industry.

WASHINGTON — The former president of Bayer HealthCare's Worldwide Consumer Care Division has won a lifetime-achievement award from a trade group focused on the OTC industry.

The Consumer Healthcare Products Association announced that it gave its Ivan D. Combe Lifetime Achievement Award to Gary Balkema at its annual executive conference in Naples, Fla.

October 31, 2012
Bayer boosts One-A-Day supplement portfolio with Schiff acquisition to the tune of $1.2 billion

Bayer HealthCare on Tuesday signed a merger agreement to acquire Schiff Nutrition International, and with that, prominent supplement brands Digestive Advantage, MegaRed, Move Free and Airborne.

MORRISTOWN, N.J. — Bayer HealthCare on Tuesday signed a merger agreement to acquire Schiff Nutrition International, and with that, prominent supplement brands Digestive Advantage, MegaRed, Move Free and Airborne. These four products accounted for 70% of all Schiff sales, noted Marijn Dekkers, Bayer CEO, during an analyst call Wednesday morning. "This acquisition will strengthen Bayer's leading OTC business and complement our existing nutritionals business with well-established strong brands," he said. 

September 28, 2012
Bayer hires Wendy Diamond for cat health campaign

Bayer HealthCare has signed a deal with a pet expert in a campaign focused on cat health, the company said Friday.

NEW YORK — Bayer HealthCare has signed a deal with a pet expert in a campaign focused on cat health, the company said Friday.

Bayer's animal health division announced that it had hired Wendy Diamond and her Russian blue cat, Pasha, to dispel popular myths about cats and promote its flea treatment, Advantage II. Diamond has appeared on television shows such as "Good Morning America" and "The Today Show" as well as in other media outlets.

April 8, 2011
Regeneron, Bayer commence phase-3 trial for diabetic macular edema treatment

Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

TARRYTOWN, N.Y. and BERLIN — Regeneron and Bayer HealthCare have initiated 1-of-2 late-stage clinical trials of their aflibercept ophthalmic solution in the treatment of a complication caused by diabetic retinopathy.

The drug makers said that it would evaluate the efficacy of VEGF Trap-Eye (aflibercept ophthalmic solution) in the treatment of diabetic macular edema, a prevalent cause of vision loss among diabetes patients, after promising results from its previous clinical trial.

February 24, 2011
Erica Mann to lead Bayer's Consumer Care division

Erica Mann has been named the new head of Bayer HealthCare’s Consumer Care division and member of the Bayer HealthCare executive committee. She will join the company March 14.

LEVERKUSEN, Germany — Erica Mann has been named the new head of Bayer HealthCare’s Consumer Care division and member of the Bayer HealthCare executive committee. She will join the company March 14.

“Over the past 25 years, Mann has become noted in the industry for her strong record of delivering business results,” stated Jörg Reinhardt, Bayer chairman. “Her outstanding experience and insights will further enable [the consumer care division] to take advantage of the sustained growth forecast for the OTC market.”